Volume

6, 4 issues

Latest issue

6:1 online 15 March 2022

Next issue

6:2 scheduled for June 2022

Back volumes

From volume 1, 2017

ISSN print

2468-4562

ISSN online

2468-4570

Aims & Scope

Kidney Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pathobiology, and pharmacology of tumors of the kidney with the objective of improving diagnosis, treatment, and survivorship in patients. The journal is directed primarily at researchers and clinicians working on these areas, with some content aimed at patients/patient advocates with these conditions. With this objective in mind, the journal publishes original research reports, systematic and regular reviews, short communications, and letters-to-the-editor in basic science, translational research and clinical medicine. The journal is committed to the highest ethical standards and best practices, and prospective authors are encouraged to consult the relevant author instructions and policies on the website at the time of submission as these are updated regularly to reflect changing guidelines.

Editorial Board

Editors-in-Chief

Primo N. Lara, Jr., MD
University of California Davis Comprehensive Cancer Center
Sacramento, CA
USA
Email: kca@iospress.com 

(Epidemiology, Pathogenesis, Pharmacology, Diagnosis, Treatment, Survivorship)

Peter Mulders, MD, PhD
Radboud UMC
Nijmegen
The Netherlands
Email: kca@iospress.com

(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment, Survivorship)

Associate Editors

Neeraj Agarwal, MD
Huntsman Cancer Institute, University of Utah, Salt Lake City
USA
(Diagnosis, Treatment, Survivorship)

Laurence Albiges, MD, PhD
Gustave Roussy, Université Paris Saclay, Villejuif
France
(Epidemiology, Pharmacology, Diagnosis, Treatment, Survivorship)

Axel Bex, MD, PhD
Netherlands Cancer Institute, Amsterdam
The Netherlands
(Epidemiology, Diagnosis, Treatment)

Toni K. Choueiri, MD
Dana-Farber Cancer Institute, Boston
USA
(Molecular Genetics, Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment, Survivorship)

Enrique Grande, MD
MD Anderson Cancer Center Madrid, Madrid
Spain
(Epidemiology, Diagnosis, Treatment, Survivorship)

Viktor Grünwald, MD
University Hospital Essen, Essen
Germany
(Etiology, Diagnosis, Treatment)

Eric Jonasch, MD
The University of Texas MD Anderson Cancer Center, Houston
USA
(Etiology, Molecular Genetics, Pharmacology, Diagnosis, Treatment, Survivorship)

Bradley C. Leibovich, MD
Mayo Clinic, Rochester
USA
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Diagnosis, Treatment)

Egbert Oosterwijk, PhD
Radboud UMC, Nijmegen
The Netherlands
(Diagnosis, Treatment, Survivorship)

Javier Puente, MD, PhD
Hospital Clinico Universitario San Carlos, Madrid
Spain
(Diagnosis, Treatment, Survivorship)

Sandy Srinivas, MD
Stanford University, Stanford
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)

Hirotsugu Uemura, MD, PhD
Kindai University Faculty of Medicine, Osaka
Japan
(Diagnosis, Treatment)

Social Media Editor

Neeraj Agarwal, MD
Huntsman Cancer Institute, University of Utah, Salt Lake City
USA
(Diagnosis, Treatment, Survivorship)

Associate Editors for Reviews

Enrique Grande, MD
MD Anderson Cancer Center Madrid, Madrid
Spain
(Epidemiology, Diagnosis, Treatment, Survivorship)

Sumanta Pal, MD
City of Hope, Duarte
USA
(Pharmacology, Diagnosis, Treatment, Survivorship)

Editor of Clinical Trials Corner

Mamta Parikh, MD
UC Davis Comprehensive Cancer Center, Sacramento
USA
(Diagnosis, Treatment, Survivorship

Editorial Board

Hideyuki Akaza, MD
University of Tokyo, Tokyo
Japan
(Pathogenesis, Diagnosis, Treatment)

Georg A. Bjarnason, MD, FRCP(C)
Sunnybrook Odette Cancer Center, Toronto, ON
Canada
(Molecular Genetics, Pharmacology, Diagnosis, Treatment, Survivorship)

James Brugarolas, MD, PhD
University of Texas Southwestern Medical Center, Dallas, TX
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Diagnosis, Treatment)

Ronald M. Bukowski, MD
Cleveland Clinic Foundation, Cleveland
USA
(Diagnosis, Treatment, Survivorship)

Steven C. Campbell, MD, PhD
Cleveland Clinic, Cleveland, OH
USA
(Epidemiology, Diagnosis, Treatment, Survivorship)

Marc Dall’era, MD
UC Davis Comprehensive Cancer Center, Sacramento, CA
USA
(Epidemiology, Diagnosis, Treatment)

Tanya B. Dorff, MD 
City of Hope, Duarte, CA
USA
(Diagnosis, Treatment)

Janice P. Dutcher, MD
Cancer Research Foundation, Chappaqua, NY
USA
(Epidemiology, Diagnosis, Treatment, Survivorship)

Tim Eisen, PhD, FRCP
University of Cambridge and Roche (VP and Global Head of GU Oncology Product Development), Cambridge
United Kingdom
(Pathobiology, Pharmacology, Diagnosis, Treatment)

Bernard Escudier, MD
Institut Gustave Roussy, Villejuif
France
(Etiology, Pathobiology, Pharmacology, Diagnosis, Treatment)

Robert A. Figlin, MD, FACP
Cedars-Sinai Medical Center, Los Angeles, CA
USA
(Pathobiology, Diagnosis, Treatment, Survivorship)

Thomas (Tom) Flaig, MD
University of Colorado School of Medicine, Aurora, CO
USA
(Diagnosis, Treatment)

Jorge Garcia, MD, FACP
University Hospitals Seidman Cancer Center Case Comprehensive Cancer Center, Cleveland, OH
USA
(Diagnosis, Treatment)

Dan George, MD
Duke University School of Medicine, Durham, NC
USA
(Epidemiology, Pathobiology, Pharmacology, Diagnosis, Treatment)

Ugo De Giorgi, MD
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola
Italy
(Diagnosis, Treatment)

Rudolfo De Guzman, MD
National Kidney and Transplant Institute, Metro Manila
Philippines
(Diagnosis, Treatment)

John Haanen, MD, PhD
Netherlands Cancer Institute, Amsterdam
The Netherlands
(Diagnosis, Treatment)

Naomi Haas, MD
University of Pennsylvania, Philadelphia, PA
USA
(Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment, Survivorship)

Hans Hammers, MD, PhD
University of Texas Southwestern, Dallas, TX
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment)

Michael R. Harrison, MD
Duke Cancer Institute, Durham, NC, USA
(Diagnosis, Treatment)

Daniel Heng, MD, MPH
Tom Baker Cancer Center, Calgary, AB
Canada
(Epidemiology, Diagnosis, Treatment, Survivorship)

Michelle S. Hirsch, MD, PhD
Brigham and Women's Hospital, Harvard Medical School, Boston, MA
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathobiology)

James J. Hsieh, MD, PhD
Washington University School of Medicine, St. Louis, MO
USA
(Molecular Genetics, Pathogenesis, Pathobiology, Diagnosis, Treatment)

Thomas Hutson, DO, PharmD
US Oncology/Baylor, Houston, TX
USA
(Pharmacology, Diagnosis, Treatment, Survivorship

Choung Soo Kim, MD, PhD
Asan Medical Center, Seoul
South Korea
(Etiology, Molecular Genetics, Pathobiology, Diagnosis, Treatment)

Christian Kollmannsberger, MD
BC Cancer Agency, Vancouver, BC
Canada
(Diagnosis, Treatment)

James Larkin, MD, PhD
The Institute of Cancer Research, London
United Kingdom
(Diagnosis, Treatment)

Marston Linehan, MD
National Cancer Institute, Bethesda, MD
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Diagnosis, Treatment)

Borje Ljungberg, MD, PhD
Umea University, Umea, Sweden
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment, Survivorship)

Axel S. Merseburger, MD, PhD
University Hospital Schleswig-Holstein, Lübeck
Germany
(Diagnosis, Treatment)

Moshe C. Ornstein, MD
Cleveland Clinic, Cleveland, OH
USA
(Diagnosis, Treatment)

Susanne Osanto, MD, PhD
Leiden University Medical Center, Leiden
The Netherlands
(Diagnosis, Treatment, Survivorship)

Stephane Oudard, MD, PhD
Hôpital Européen Georges Pompidou, Paris
France
(Diagnosis, Treatment)

Allan J. Pantuck, MD
UCLA Institute of Urologic Oncology, Los Angeles
USA
(Molecular Genetics, Pathogenesis, Pharmacology, Diagnosis, Treatment)

Elizabeth Plimack, MD
Fox Chase Cancer Center, Philadelphia, PA
USA
(Diagnosis, Treatment, Survivorship)

Camillo Porta, MD
IRCCS San Matteo University Hospital Foundation, Pavia
Italy
(Diagnosis, Treatment)

Thomas Powles, MD
The Royal Free NHS Trust and Barts Cancer Institute, London
United Kingdom
(Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment)

W. Kimryn Rathmell, MD, PhD
Vanderbilt-Ingram Cancer Center, Nashville, TN
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment)

Brian Rini, MD
Cleveland Clinic, Cleveland, OH
USA
(Epidemiology, Etiology, Pathogenesis, Pathobiology, Diagnosis, Treatment, Survivorship)

Paul Russo, MD
Memorial Sloan Kettering Cancer Center, New York, NY
USA
(Diagnosis, Treatment)

Christopher Ryan, MD
Oregon Health Science University, Portland, OR
SA
(Diagnosis, Treatment)

Manuela Schmidinger, MD
Medical University of Vienna, Vienna
Austria
(Epidemiology, Pharmacology, Diagnosis, Treatment, Survivorship)

Brian Shuch, MD
Yale School of Medicine/Smilow Cancer Center, New Haven, CT
USA
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Diagnosis, Treatment)

Ramaprasad Srinivasan, MD, PhD
National Cancer Institute, Bethesda, MD
USA
(Epidemiology, Etiology, Molecular Genetics, Pathogenesis, Diagnosis, Treatment)

Walter Stadler, MD
University of Chicago, Chicago, IL
USA
(Epidemiology, Pharmacology, Diagnosis, Treatment)

Mark Stein, MD
Rutgers, The State University of New Jersey, New Brunswick, NJ
USA
(Diagnosis, Treatment)

Cora N. Sternberg, MD
San Camillo and Forlanini Hospitals, Rome
Italy
(Diagnosis, Treatment)

Cezary Szczylik, MD, PhD
Oncology Military Medical Institute, Warsaw
Poland
(Diagnosis, Treatment)

Nizar M. Tannir, MD
MD Anderson Cancer Center, Houston, TX
USA
(Epidemiology, Pharmacology, Diagnosis, Treatment)

Yoshihiko Tomita, MD, PhD
Niigata University, Niigata
Japan
(Diagnosis, Treatment)

Ilya Tsimafeyeu, MD
Kidney Cancer Research Bureau, Russian Society of Clinical Oncology, Moscow
Russia
(Diagnosis, Treatment)

Robert G. Uzzo, MD
Fox Chase Cancer Center, Philadelphia, PA
USA
(Epidemiology, Etiology, Diagnosis, Treatment)

Ulka Vaishampayan, MD
University of Michigan, Rogel Cancer Center, Ann Arbor, MI
USA
(Epidemiology, Pathogenesis, Pharmacology, Diagnosis, Treatment, Survivorship)

Guillermo de Velasco, MD, PhD
Hospital Universitario 12 de Octubre, Madrid
Spain
(Diagnosis, Treatment)

Nicholas J. Vogelzang, MD
Comprehensive Cancer Centers of Nevada (CCCN), Las Vegas, NV
USA
(Diagnosis, Treatment, Survivorship)

Martin H. Voss, MD
Memorial Sloan Kettering Cancer Center, New York, NY
USA
(Etiology, Molecular Genetics, Pathogenesis, Pathobiology, Pharmacology, Diagnosis, Treatment)

Stenio Zequi, MD, PhD
AC Camargo Cancer Center, Sao Paulo
Brazil
(Epidemiology, Diagnosis, Treatment)

Patricia Zondervan, MD, PhD
Amsterdam UMC, Amsterdam
The Netherlands
(Etiology, Molecular Genetics, Diagnosis, Treatment)

Author Guidelines

By submitting my article to this journal, I agree to the Author Copyright Agreement, the IOS Press Ethics Policy, and the IOS Press Privacy Policy.

See instructions to authors.

Abstracted/Indexed in

Embase
Google Scholar
Scopus
Web of Science: Emerging Sources Citation Index

Open Access

By default, articles published in Kidney Cancer are available only to institutions and individuals with access rights. However, the journal offers all authors the option to purchase open access publication for their article as part of the IOS Press Open Library. This means that the final published version will be freely available to anyone worldwide, indefinitely, under a Creative Commons license and without the need to purchase access to the article. This is also referred to as “gold” open access.

Gold open access pricing
Authors who choose gold open access publication will be subject to an article publication charge of € 1250 / US$ 1450 for publication under the CC BY-NC 4.0 license or € 1850 / US$ 2080 for publication under the CC BY 4.0 license. Pricing is exclusive of possible taxes. After an article is accepted for publication, the corresponding author will be informed regarding the open access option during the production stages, and will have the opportunity to purchase open access for their article. It could be that the open access fee of an article is waived completely due an institutional agreement IOS Press has with the corresponding authors' institution. Please check the institutional agreements page for details.

Green open access
Authors who do not make use of the gold open access option may still make their article freely available using self-archiving, also referred to as green open access. Authors may make their final accepted manuscript available for free download from their personal or institutional website or institutional archive. This model is free for the author.

PubMedCentral deposits
This journal deposits open access articles in PubMedCentral (PMC) as part of the IOS Press Open Library but can only do so if the article received NIH funding or if any of the authors are NIH, or associated partners, employees. Please refer to the PMC Funder Deposit List at the NIH Public Access Policy for details.

Peer Review Policy

Kidney Cancer operates a rigorous, timely, blinded peer review process (single blind by default, with an option for double-blind if requested) by experts in the field. This means that the identity of the authors is known to the reviewers but the identity of the reviewers is not communicated to the authors. 

Please visit our reviewer guidelines for further information about how to conduct a review.

After automatic plagiarism screening through iThenticate, all submitted manuscripts are subjected to initial appraisal by the Editors-in-Chief.

Manuscripts that are deemed unsuitable may be rejected without external review by the Editors-in-Chief and/or the Associate Editors and the authors will be informed as soon as possible.

Reasons to reject a paper in the pre-screening process could for example be because the work does not fall within the aims and scope of the Journal, the writing is of poor quality, the instructions to authors were not followed or the presented work is not novel.

If found suitable for further consideration, manuscripts are forwarded to an Associate Editor(AE) with expertise in the area who performs an second review and if determined to be of sufficient interest, then recruits appropriate referees. The AE will invite a sufficient number of reviewers to obtain at least 2 reviews.

Reviewers are asked to recuse themselves from reviewing a submission if a conflict makes them unable to make an impartial scientific judgment or evaluation. Conflicts of interest include, but are not limited to: collaboration with the authors in the past three years; any professional or financial affiliations that may be perceived as a conflict of interest; a history of personal differences with the author(s). The Editors-in-Chief strive to ensure a typical turnaround time of 3 months from submission to final determination of status.

Reviewers are asked to judge a paper on at least:

  • Significance to field
  • Relevance to journal
  • Methodology
  • Data analysis
  • Literature review
  • Writing style/clarity

Based on the received reviews the Associate Editor will write a decision letter, choosing one of the following categories:

  • Accept

The manuscript is suitable for publication and only requires minor polishing; thus, no further reviews are requested.

  • Minor revisions required

The authors are required to make moderate changes to their manuscript. The manuscript becomes acceptable for publication if the changes proposed by the reviewers and editors are successfully addressed. The revised manuscript will be examined by the Associate Editor and possibly sent back to all (or a selection of) reviewers for a second round of reviews. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.

  • Major revisions required

The manuscript cannot be accepted for publication in its current form. However, a major revision addressing all issues raised by the reviewers may be acceptable for publication. The revised manuscript will undergo a full second round of review. Authors are requested to provide a letter to the reviewers detailing the improvements made for the resubmission.

  • Revise and resubmit

In its current form, the manuscript is not suitable for publication. A resubmission would require substantial revisions and is only encouraged in special cases. The resubmitted manuscript will be considered as a new submission.

  • Reject

The manuscript is rejected as it is deemed to be out of scope, not relevant, or not meeting the journal’s quality standards in terms of significance, novelty, and/or presentation.

The Editors-in Chief may perform a secondary review and suggest additional revisions. After final inspection and approval of the decision letter by the Editors-in-Chief the authors are notified of the decision.

Once accepted, manuscripts are normally published on-line without delay (with the date of publication indicated) and appear in the next available print issue (published quarterly).

Co-authors who are also members of the Editorial Board are not involved in any way with the peer review process of articles of their (co-)authorship, and are asked to disclose this information in the Conflict of Interest section.

 

The Editors-in-Chief have ultimate responsibility for what is published in the journal. 

Authors may appeal decisions by contacting the Editors-in-Chief (at kca@iospress.com). 

The Editors-in-Chief aim to inform authors in writing of the result of their appeal within 14 days.

Archives of original submissions, referee reports, revisions and correspondence for both accepted and rejected manuscripts are kept indefinitely.

Stay Updated – To receive alerts of new issues and other journal news, be sure to sign up to the Kidney Cancer newsletter via this link & you can read the latest newsletter here.

Social Media – Follow the journal on Twitter and keep updated as the social media editor Neeraj Agarwal, MD shares our journal content and news of interest to the kidney cancer research community. Join in the discussion with our research community!

Emerging Sources Citation Index – As of July 2021, Kidney Cancer is covered in the Emerging Sources Citation Index in the Web of Science.

APCs Waived – Article processing charges (APCs) are currently waived for Kidney Cancer and articles are published open access.

Kid. Can. Assoc. Partnership – As of Nov 2017, a new partnership was announced between the Kidney Cancer Association (kidneycancer.org) and our journal Kidney Cancer, which is a forum for important scientific advancements and the advocacy community.

Latest Articles

Discover the contents of the latest journal issue:

In Memoriam: Chris Wood
Peter Mulders, Primo N. Lara

“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer
Brittney H. Cotta, Hannah Bell, Simpa S. Salami, Hyung Kim, Ulka Vaishampayan

Patient-Derived Renal Cell Carcinoma Xenografts Capture Tumor Genetic Profiles and Aggressive Behaviors
Ethiene C. Estevan, Adriano O. Beserra, Stephania M. Bezerra, Giovana T. Torrezan, Amanda Ikegami, Humberto Dellê, Isabela W. Cunha, Isabella T. Meira, Dirce M. Carraro, Primo N. Lara, Stenio C. Zequi, Vilma R. Martins, Tiago G. Santos

BRCA1-Associated Protein 1 (BAP-1) as a Prognostic and Predictive Biomarker in Clear Cell Renal Cell Carcinoma: A Systematic Review
Melissa Previtera, Shuchi Gulati, Primo N. Lara

Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis
Ishan Patel, Amit Joshi, Pratiksha Kapse, Manmohan Singh

Kidney Cancer is media partner of EAU22
 

EAU congress banner

KidCanAssoc banner on KCA

Sustainable Development Goals

This journal supports IOS Press' actions relating to the Sustainable Development Goals (SDGs) and commits to the Diversity and Inclusion Statement.

KCA geo data visual on dark blue background

More information will be available in due course. Check the SDGs page for updates.